Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia
Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia
This study investigated the effectiveness and safety of SoracteLite ™- Trans-Perineal Laser
 ablation (TPLA) in the treatment of patients with symptomatic Benign Prostatic Hyperplasia
 (BPH) at 6 and 12 months follow-up
The purpose of this study was to investigate the effectiveness and safety of SoracteLite ™ -
 Trans-Perineal Laser ablation (TPLA) in the treatment of patients with symptomatic benign
 prostatic hyperplasia (BPH) at 6 and 12 months follow-up. Methods: Patients with urinary
 symptoms secondary to BPH underwent TPLA under local anaesthesia in four centers. Under US
 guidance, up to four 21G applicators were inserted in the prostatic tissue. Each treatment
 was performed with diode laser operating at 1064 nm changing the illumination time according
 to prostate size.
Inclusion Criteria:

 -  Male

 -  ≥ 50 years of age

 -  International Prostate Symptoms (IPSS) ≥12

 -  Peak urinary flow rate (Qmax): <15 ml

 -  Prostate volume: ≥ 30 ml, measured by transrectal ultrasound

 -  Post-void residual (PVR): <400 ml

 -  Signed informed consent

 Exclusion Criteria:

 -  MRI signs of malignancy confirmed by biopsy investigation

 -  urethral stenosis

 -  serious coagulation disorders

 -  inadequate compliance

 -  ischemic pathology in the previous six months

 -  active phase inflammatory pathology